The FDA approves UCB's (OTCPK:UCBJF) Cimzia (certolizumab pegol) for the treatment of non-radiographic axial spondyloarthritis, a type of inflammatory arthritis commonly associated with lower back pain (non-radiographic means that there are symptoms but no visible damage on X-rays). This is the first approved medication in the US for the indication. Source: Seeking Alpha 28/3/2019